Clinical trial

Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index

NCT05728268

Study summary

ClinicalTrials.gov

Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention dose-dense nab-paclitaxel followed by EC Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2021-08-01

PhasePHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

Interventions

dose-dense nab-paclitaxel followed by ECDRUG

Sponsors & collaborators

Shantou Central Hospitallead sponsor

Shantou University Medical Collegecollaborator

Jieyang People's Hospitalcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05728268 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.